



Mylan Files Lawsuit Against Pittsburgh Post-Gazette

PITTSBURGH, Aug. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that the company and its subsidiary Mylan Pharmaceuticals Inc. filed a civil lawsuit in the Circuit Court of Monongalia County, W.Va., against the Pittsburgh Post-Gazette, Post-Gazette reporters Len Boselovic and Patricia Sabatini, and others as yet unknown.

The lawsuit was filed after the newspaper published a series of sensational and misleading articles based on improperly obtained and misconstrued confidential internal documents. The articles mischaracterized a minor deviation from an internal Mylan procedure, creating the false appearance of significant quality and regulatory issues at Mylan's Morgantown, W.Va., plant when no such issues existed. The U.S. Food and Drug Administration (FDA) recently concluded a review at the facility and determined that there were no deficiencies and that no action was required.

The lawsuit seeks, among other things, the return of the internal confidential and proprietary documents in the Post-Gazette's possession that were improperly obtained without Mylan's knowledge or consent. The lawsuit challenges what the Post-Gazette has described as proper news-gathering techniques as well as the improper distribution of Mylan's internal documents to others who then reviewed them without the complete set of facts. This contributed to the noted mischaracterizations and misleading allegations in the numerous articles published on this matter.

In addition to recovery of its internal documents, Mylan also seeks to recover compensatory, exemplary and other appropriate relief from the named defendants and any others, as yet unknown, who were involved in or possibly benefitted from the wrongful conduct.

Mylan Chairman and CEO Robert J. Coury said: "We are very disappointed that this situation occurred and reached this level, however, we have no other alternative but to address this type of misconduct. This matter has now been turned over to Mylan's legal department, and as consistent with our long-time policy not to comment on litigation, we will not be discussing this matter going forward. Mylan's management team will continue to maintain its unwavering focus on executing and delivering on its long-standing objectives."

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

CONTACT: Media, Michael Laffin, +1-724-514-1968; or Investors, Dan Crookshank, +1-724-514-1813, both of Mylan Inc.